NDAINJECTIONSOLUTION
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIVFLOZA (nedosiran) is an oligonucleotide injection approved by FDA in September 2023 for a rare metabolic disorder. The drug works through RNA interference mechanism to reduce disease-causing protein production. Patient administration is via subcutaneous or intravenous injection.
Growth12.2 years to LOE
Early-stage growth product with no current competitive pressure; commercial team is building market presence in rare disease segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
Started Feb 2022
27 enrolled
Primary HyperoxaluriaPrimary Hyperoxaluria Type 1Primary Hyperoxaluria Type 2+1 more
Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
Primary Hyperoxaluria Type 1 (PH1)
Career Relevance
RIVFLOZA represents a niche opportunity in rare disease commercialization where specialized expertise in orphan drug development, reimbursement, and patient advocacy is highly valued. Career trajectory depends on building deep knowledge of primary hyperoxaluria patient pathways and establishing yourself as a rare disease therapeutic expert.
Worked on RIVFLOZA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.